secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-110375
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q3 revenue down 16% YoY to $6.8M; reiterates FY2025 guidance
--------------------------------------------------------------------

- Total revenue $6.8M (-16% YoY); core revenue $6.4M (-21% YoY).
- Net loss $12.4M vs $11.6M loss in Q3 2024; adjusted EBITDA loss $10.0M.
- Added 4 new SPL clients in 2025 (latest Moonlight Bio in Oct); total SPLs now 32.
- Reiterates FY2025 guidance: core revenue flat/-10% YoY; SPL program revenue ~$5M.
- Operational restructuring announced Sep 22 to reduce costs; cash at $158M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465925110375/0001104659-25-110375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465925110375/mxct-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer